Source:http://linkedlifedata.com/resource/pubmed/id/12931226
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
2003-10-24
|
| pubmed:abstractText |
In the setting of reduced-intensity conditioning (RIC) regimens for allogeneic stem cell transplantation (allo-SCT), the epidemiology of transplant-related infections is still poorly defined. In 101 high-risk patients who received an HLA-identical sibling allo-SCT after RIC, including fludarabine, busulfan and antithymocyte globulin (ATG), we report during the first 6 months a cumulative incidence of positive CMV antigenemia of 42% (95% CI 32-52%), developing at a median of 37 (range 7-116) days without evidence of CMV disease (median follow-up, 434 days). The cumulative incidence of bacteremia was 25% (95% CI 17-33%), occurring at a median of 67 (range 7-172) days, while patients had recovered a full neutrophil count. In all, 65% of the bacteremia (95% CI 49-81%) were gram negative. The cumulative incidence of fungal infections was 8% (95% CI 3-13%), with a median onset of 89 (range 7-170) days. In multivariate analysis, stem cell source (bone marrow; P=0.0002) was significantly associated with the risk of positive CMV antigenemia, while higher doses of prednisone (>2 mg/kg) represented the major risk factor for bacteremia (P=0.0001). Infectious-related mortality was 5% (95% CI 1-9%), with aspergillosis being the principal cause. Collectively, these results suggest that prospective efforts are warranted to develop optimal antimicrobial preventive strategies after RIC allo-SCT.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0887-6924
|
| pubmed:author |
pubmed-author:BilgenOO,
pubmed-author:BlaiseDD,
pubmed-author:ChoufiBB,
pubmed-author:ColletLL,
pubmed-author:CosoDD,
pubmed-author:FauchetAA,
pubmed-author:FoxG EGE,
pubmed-author:GastautJ AJA,
pubmed-author:JacotWW,
pubmed-author:MaraninchiDD,
pubmed-author:MohtyMM,
pubmed-author:OlivaHH,
pubmed-author:StoppaA MAM,
pubmed-author:TournilhacOO,
pubmed-author:VeyNN,
pubmed-author:ViensPP,
pubmed-author:ZandottiCC
|
| pubmed:issnType |
Print
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2168-77
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:12931226-ABO Blood-Group System,
pubmed-meshheading:12931226-Adolescent,
pubmed-meshheading:12931226-Adult,
pubmed-meshheading:12931226-Aged,
pubmed-meshheading:12931226-Antiviral Agents,
pubmed-meshheading:12931226-Bacteremia,
pubmed-meshheading:12931226-Bacterial Infections,
pubmed-meshheading:12931226-Blood Group Incompatibility,
pubmed-meshheading:12931226-Cytomegalovirus Infections,
pubmed-meshheading:12931226-Female,
pubmed-meshheading:12931226-Ganciclovir,
pubmed-meshheading:12931226-Graft Rejection,
pubmed-meshheading:12931226-Graft vs Host Disease,
pubmed-meshheading:12931226-Histocompatibility Testing,
pubmed-meshheading:12931226-Humans,
pubmed-meshheading:12931226-Incidence,
pubmed-meshheading:12931226-Male,
pubmed-meshheading:12931226-Middle Aged,
pubmed-meshheading:12931226-Siblings,
pubmed-meshheading:12931226-Stem Cell Transplantation,
pubmed-meshheading:12931226-Survival Analysis,
pubmed-meshheading:12931226-Time Factors,
pubmed-meshheading:12931226-Transplantation, Homologous,
pubmed-meshheading:12931226-Virus Diseases
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen.
|
| pubmed:affiliation |
Unité de Transplantation et de Thérapie Cellulaire, Institut Paoli-Calmettes, Marseille, France.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|